Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials.

Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Kim EE, Lee DS, Chung JK.

J Korean Med Sci. 2014 Jun;29(6):811-7. doi: 10.3346/jkms.2014.29.6.811. Epub 2014 May 30.

2.

Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.

Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ.

J Nucl Med. 2008 May;49(5):764-70. doi: 10.2967/jnumed.107.049072. Epub 2008 Apr 15.

3.

Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.

Tu J, Wang S, Huo Z, Lin Y, Li X, Wang S.

Radiother Oncol. 2014 Jan;110(1):25-30. doi: 10.1016/j.radonc.2013.12.018. Epub 2014 Jan 28. Review.

PMID:
24485353
4.

Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.

Vrachimis A, Schober O, Riemann B.

Nuklearmedizin. 2012;51(3):67-72. doi: 10.3413/Nukmed-0432-11-10. Epub 2012 Feb 1.

PMID:
22294096
5.

Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008302. doi: 10.1002/14651858.CD008302.pub2. Review.

PMID:
21069705
6.

Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.

Fu H, Ma C, Tang L, Wu F, Liu B, Wang H.

Q J Nucl Med Mol Imaging. 2015 Mar;59(1):121-8. Epub 2014 May 21. Review.

PMID:
24844252
7.

Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.

Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):162-8. doi: 10.1016/j.clon.2011.02.011. Epub 2011 Mar 15.

PMID:
21411300
8.

Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.

Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S.

Thyroid. 2010 Mar;20(3):257-63. doi: 10.1089/thy.2009.0401.

PMID:
20187781
9.

Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.

Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O.

Clin Endocrinol (Oxf). 2009 Jul;71(1):115-23. doi: 10.1111/j.1365-2265.2008.03424.x. Epub 2008 Sep 18.

PMID:
18803678
10.

Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.

Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM.

Thyroid. 2012 Oct;22(10):1007-15. doi: 10.1089/thy.2012.0183. Epub 2012 Aug 8.

PMID:
22873801
11.

Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.

Tresoldi AS, Sburlati LF, Rodari M, Schinkelshoek M, Perrino M, De Leo S, Montefusco L, Colombo P, Arosio M, Lania AG, Fugazzola L, Chiti A.

J Endocrinol Invest. 2014 Aug;37(8):709-14. doi: 10.1007/s40618-014-0088-3. Epub 2014 May 21.

PMID:
24844565
12.

High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.

Bartenstein P, Calabuig EC, Maini CL, Mazzarotto R, Muros de Fuentes MA, Petrich T, Rodrigues FJ, Vallejo Casas JA, Vianello F, Basso M, Balaguer MG, Haug A, Monari F, Vaňó RS, Sciuto R, Magner J.

Thyroid. 2014 Mar;24(3):480-7. doi: 10.1089/thy.2013.0157. Epub 2014 Jan 17.

PMID:
24040896
13.

Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.

Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, Eising EG, Knust EJ, Bockisch A, Jentzen W.

Exp Clin Endocrinol Diabetes. 2010 Jul;118(7):393-9. doi: 10.1055/s-0029-1225350. Epub 2009 Oct 23.

PMID:
19856257
14.

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C.

J Nucl Med. 2006 Apr;47(4):648-54.

15.

Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.

Ciappuccini R, Hardouin J, Heutte N, Vaur D, Quak E, Rame JP, Blanchard D, de Raucourt D, Bardet S.

Eur J Endocrinol. 2014 Aug;171(2):247-52. doi: 10.1530/EJE-14-0192. Epub 2014 May 27.

17.

Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.

Rosario PW, Xavier AC, Calsolari MR.

Thyroid. 2010 Nov;20(11):1247-52. doi: 10.1089/thy.2010.0114. Epub 2010 Oct 18.

PMID:
20950256
18.

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F.

Endocr Relat Cancer. 2005 Mar;12(1):49-64. Review.

19.

Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

van der Horst-Schrivers AN, Sluiter WJ, Muller Kobold AC, Wolffenbuttel BH, Plukker JT, Bisschop PH, de Klerk JM, Al Younis I, Lips P, Smit JW, Brouwers AH, Links TP.

PLoS One. 2015 Mar 20;10(3):e0120184. doi: 10.1371/journal.pone.0120184. eCollection 2015.

20.

Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods.

Vallejo Casas JA, Mena Bares LM, Gálvez MA, Marlowe RJ, Latre Romero JM, Martínez-Paredes M.

Nucl Med Commun. 2011 Sep;32(9):840-6. doi: 10.1097/MNM.0b013e32834863b0.

PMID:
21691237
Items per page

Supplemental Content

Write to the Help Desk